GlassScriptPhysician profile
James Giebink
NPI 1689652091
$10,175.46
in general payments reported to CMS, 2019-2025
36 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 84% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,556 · 2020: $630 · 2021: $2,147 · 2022: $1,283 · 2023: $2,049 · 2024: $1,487 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,558.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,429.08 | 2019-2025 | Tagrisso, Datroway, Calquence |
| Genentech USA, INC. | $910.88 | 2019-2023 | Lunsumio |
| Incyte Corporation | $749.70 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Janssen Biotech, INC. | $649.16 | 2020-2025 | Carvykti, Rybrevant, Darzalex |
| Amgen INC. | $632.20 | 2019-2025 | Blincyto, Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $610.79 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $404.98 | 2019-2023 | Keytruda |
| Lilly USA, LLC | $403.26 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $387.82 | 2019-2024 | Libtayo |
| Daiichi Sankyo INC. | $284.18 | 2021-2022 | |
| Beigene USA, INC. | $251.05 | 2021-2023 | Brukinsa |
| Genzyme Corporation | $250.75 | 2021-2024 | |
| Exelixis INC. | $248.72 | 2021-2022 | |
| Gilead Sciences, INC. | $246.38 | 2023-2024 | Trodelvy |
| Novocure INC. | $229.48 | 2023 | Optune |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $225.74 | 2021-2023 | Tazverik |
| Kite Pharma, INC. | $209.72 | 2021-2023 | Yescarta |
| Eisai INC. | $206.21 | 2019-2021 | |
| Taiho Oncology, INC. | $141.30 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.84 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $132.49 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $124.46 | 2023 | |
| Recordati_rare_diseases_inc. | $124.46 | 2024 | Sylvant |
| Abbvie INC. | $124.46 | 2025 | |
| Mirati Therapeutics, INC. | $120.65 | 2023 | Krazati |
| Pfizer INC. | $119.31 | 2020-2023 | |
| Emd Serono, INC. | $117.44 | 2019 | |
| Puma Biotechnology, INC. | $116.68 | 2020 | |
| Immunomedics, INC. | $114.47 | 2020 | |
| G1 Therapeutics, INC. | $110.30 | 2021 | |
| Geron Corporation | $101.87 | 2024 | Rytelo |
| Astellas Pharma US INC | $99.06 | 2019 | |
| Servier Pharmaceuticals LLC | $87.98 | 2024 | |
| Seagen INC. | $44.23 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.96 | 2022 | |
| Organon LLC | $10.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Giebink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.